Repeated false reactive ADVIA centaur® and bio-rad Geenius™ HIV tests in a patient self-administering anabolic steroids.
Anabolic steroids
Bio-rad Geenius
False positive HIV test
False reactive HIV screen
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
29
10
2019
accepted:
22
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
7
3
2020
Statut:
epublish
Résumé
An individual is considered HIV positive when a confirmatory HIV-1/HIV-2 differentiation test returns positive following an initial reactive antigen/antibody combination screen. Falsely reactive HIV screens have been reported in patients with various concomitant infectious and autoimmune conditions. Falsely positive confirmatory HIV differentiation assays are seen less frequently, but have been observed in cases of pregnancy, pulmonary embolism, and malaria. A healthy 27 year-old man was referred after a reactive ADVIA Centaur® HIV Ag/Ab screen and positive Bio-Rad Geenius™ HIV 1/2 Confirmatory assay, suggesting HIV-1 infection. The patient's HIV viral load was undetectable prior to initiation of antiretroviral therapy, and remained undetectable on subsequent testing after initiation of antiretroviral therapy. Both Centaur® and Geenius™ tests were repeated and returned reactive. As this patient was believed to be at low risk of acquiring HIV infection, samples were additionally run on Genscreen™ HIV-1 Ag assay and Fujirebio Inno-LIA™ HIV-1/2 score, with both returning non-reactive. For confirmation, the patient's proviral HIV DNA testing was negative, confirming the initial results as being falsely positive. The patient disclosed that he had been using a variety of anabolic steroids before and during the time of HIV testing. The erroneous diagnosis of HIV can result in decreased quality of life and adverse effects of antiretroviral therapy if initiated, hence the importance of interpreting the results of HIV testing in the context of an individual patient. This reports suggests a potential association between the use of anabolic steroids and falsely-reactive HIV testing.
Sections du résumé
BACKGROUND
BACKGROUND
An individual is considered HIV positive when a confirmatory HIV-1/HIV-2 differentiation test returns positive following an initial reactive antigen/antibody combination screen. Falsely reactive HIV screens have been reported in patients with various concomitant infectious and autoimmune conditions. Falsely positive confirmatory HIV differentiation assays are seen less frequently, but have been observed in cases of pregnancy, pulmonary embolism, and malaria.
CASE PRESENTATION
METHODS
A healthy 27 year-old man was referred after a reactive ADVIA Centaur® HIV Ag/Ab screen and positive Bio-Rad Geenius™ HIV 1/2 Confirmatory assay, suggesting HIV-1 infection. The patient's HIV viral load was undetectable prior to initiation of antiretroviral therapy, and remained undetectable on subsequent testing after initiation of antiretroviral therapy. Both Centaur® and Geenius™ tests were repeated and returned reactive. As this patient was believed to be at low risk of acquiring HIV infection, samples were additionally run on Genscreen™ HIV-1 Ag assay and Fujirebio Inno-LIA™ HIV-1/2 score, with both returning non-reactive. For confirmation, the patient's proviral HIV DNA testing was negative, confirming the initial results as being falsely positive. The patient disclosed that he had been using a variety of anabolic steroids before and during the time of HIV testing.
DISCUSSION AND CONCLUSIONS
CONCLUSIONS
The erroneous diagnosis of HIV can result in decreased quality of life and adverse effects of antiretroviral therapy if initiated, hence the importance of interpreting the results of HIV testing in the context of an individual patient. This reports suggests a potential association between the use of anabolic steroids and falsely-reactive HIV testing.
Identifiants
pubmed: 31906866
doi: 10.1186/s12879-019-4722-8
pii: 10.1186/s12879-019-4722-8
pmc: PMC6945705
doi:
Substances chimiques
HIV Antibodies
0
Testosterone Congeners
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Références
J Virol Methods. 2007 Jul;143(1):86-94
pubmed: 17395277
J Clin Virol. 2017 Jul;92:62-68
pubmed: 28535437
J Virol Methods. 2010 Dec;170(1-2):16-20
pubmed: 20723562
PLoS One. 2013;8(3):e59906
pubmed: 23527284
J Clin Microbiol. 2010 May;48(5):1570-7
pubmed: 20181896
J Clin Virol. 2013 Dec;58 Suppl 1:e85-91
pubmed: 24342484
AIDS Res Ther. 2016 Jan 05;13:1
pubmed: 26734067
J Virol Methods. 2014 Sep;206:1-4
pubmed: 24877900
J Clin Microbiol. 2019 May 24;57(6):null
pubmed: 30944187
J Clin Virol. 2014 Aug;60(4):399-401
pubmed: 24932737
PLoS One. 2018 Oct 31;13(10):e0198924
pubmed: 30379808
Int J Infect Dis. 2019 Jun;83:86-87
pubmed: 30986542
J Clin Virol. 2018 Jul;104:23-28
pubmed: 29704735
Ann Lab Med. 2013 Nov;33(6):420-5
pubmed: 24205491
AJR Am J Roentgenol. 2005 Jan;184(1):14-9
pubmed: 15615943
Open Forum Infect Dis. 2018 Sep 26;5(9):ofy197
pubmed: 30276221